Deals
AstraZeneca quietly acquires Six Peaks, plus deals involving Bayer/Dare, Tempest/Factor, XenoTherapeutics/Repare, DayOne/Mersana and more.
Tessera, which claims its gene-writing technology offers functionality beyond gene-editing, hopes Regeneron can accelerate development of its preclinical alpha-1 antitrypsin deficiency drug.
Three big pharma business development heads at the recent Jefferies conference discussed their activities in 2025, and offered some advice to potential partners on how to avoid deal talks breaking down.
Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.
Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.
Deal Snapshot: The biotech is joining forces with the Versant Ventures-backed startup, paying $50m upfront to apply its macrocycle peptide platform to immunological diseases.
Cidara’s long-acting antibody candidate could help protect millions of immunocompromised patients against flu – and could work around growing vaccine hesitancy in the US.
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Plus deals involving Adagene/Third Arc, Celltrion/TRiOar, Celltrion/Kaigene, ImmunoScape/Cue, Laekna/Qilu, Lilly/ABL, Lilly/Sanegene, Sanyou/ZJ Bio-Tech, TransThera/Neurocrine, Qyuns/Roche, Otsuka/4D Molecular, IASO/GC Cell, Chugai/Renalys, Henlius/Forlong and Teijin/Elevara.
Deal Snapshot: Merck KGaA is looking to bolster its neuroscience pipeline with novel drugs for Parkinson’s disease and will team with Valo Health on AI-driven discovery work.
The drugmaker increased its offer to $21 per share – equal to Lundbeck’s counteroffer – with the same $1.50 CVR tied to Lumryz’s approval, which Avadel called superior.
Forced to spend more than it wanted on Metsera, Pfizer’s M&A coffers are now depleted but it is still interested in weight loss pills and immunology & inflammation assets.
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Buoyed by the milestone AbbVie deal, Glenmark expects to “pay down” its debt and is also changing certain legacy practices as it seeks to ascend the value chain to become more of a branded company.
Looking to enhance its Erleada-led prostate cancer portfolio, Johnson & Johnson will acquire Halda and its Regulated Induced Proximity TArgeting Chimera technology.
A rush of bigger M&A deals is inspiring renewed confidence in the biotech sector, but US companies are facing up to unprecedented competition from China.
Merck & Co. is looking to bolster its respiratory portfolio with Cidara’s Phase III antiviral conjugate CD388, previously owned by Janssen. Phase III data are expected in 2027.
The Danish drugmaker is offering more per share in cash and CVRs than Alkermes did in the deal announced in October.
Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline
The German group is looking at ‘single digit billion’ opportunities, chief financial officer Helene von Roeder tells Scrip.